Background: Botulinum neurotoxin type A (BoNT/A) is the active substance in preparations used for the highly effective treatment of neurologic disorders such as cervical dystonia, blepharospasm, or spasticity, as well as other indications such as axillary and palmar hyperhidrosis, and urologic disorders. Objective: To determine the amount of BoNT/A protein present in pharmaceutical preparations of Botox
urologic disorders. [3] BoNT/A containing therapeutics are also used in aesthetic dermatology to treat facial wrinkles (e.g. glabella lines). [4] There are several BoNT/A containing products on the market: Botox Ò /Vistabel Ò (Allergan Inc., Irvine, CA, USA), Dysport Ò /Azzalure Ò (Ipsen, Slough, UK/Galderma, Paris, France), and Xeomin Ò /Bocouture Ò (NT 201; Merz Pharmaceuticals GmbH, Frankfurt, Germany). In all three products, the neurotoxin is derived from the identical Hall strain of Clostridium botulinum type A. For the following discussion, these products will be referred to as Botox Ò , Dysport Ò , and Xeomin Ò , regardless of their clinical indication because the product compositions do not differ between indications.
The BoNT/A protein has a molecular weight of 150 kD, consisting of a light chain (50 kD) and a heavy chain (100 kD); both chains have different functions in the neurotoxin's mechanism of action. [5] Whereas Xeomin Ò contains only the 150 kD neurotoxin, the 150 kD neurotoxin in Botox Ò and Dysport Ò is part of a complex with other proteins (complexing proteins), which play no role in the mechanism of action. Botox Ò is composed of a 900 kD complex, [6] with one molecule of the 150 kD neurotoxin per complex. [7] The biochemical composition of Dysport Ò is unknown. In an early publication, it was reported that a similar purification process to that used for the drug substance in Dysport Ò produces a mixture composed of the L complex (600 kD) and M complex (300 kD). [8] These findings were later supplemented by protein composition analyses of the drug substance in Dysport Ò . [9] The biologic activity of all BoNT/A containing products is given in units relating to the dose that is lethal to 50% of mice tested (LD 50 ); however, the assay procedure used to determine biologic activity can differ between companies. Indeed, the most informative comparisons of BoNT/A containing products have been made in clinical studies. In a 16-week, randomized, double-blind, non-inferiority trial in 463 patients with cervical dystonia, [10] Xeomin Ò was shown to be as effective as Botox Ò with a comparable adverse event profile when a clinical conversion ratio of 1 U : 1 U was used. Moreover, in a double-blind, noninferiority trial in 300 patients with blepharospasm, treatment with Xeomin Ò was as effective as and as safe as Botox Ò (using a 1 U : 1 U conversion ratio) when assessed by the Jankovic Rating Scale. [11] This equipotency of Botox Ò and Xeomin Ò , when used at a clinical conversion ratio of 1 U : 1 U, was also confirmed in a comparative trial in the treatment of glabellar frown lines in 381 patients.
[12] The 1 U : 1 U ratio was not unexpected because both products have demonstrated the same activity in a potency assay, which showed that five different batches of Botox Ò contained a mean of 101.7 -6.2 LD 50 units per vial and five different batches of Xeomin Ò contained a mean of 103.0 -5.7 LD 50 units per vial.
[13] Thus, both clinical and preclinical analyses have demonstrated a 1 : 1 ratio between Botox Ò and Xeomin Ò . [14] In contrast, the conversion ratio between Dysport Ò and Botox Ò or Xeomin Ò is not yet clear. Conversion ratios of up to 6 : 1 (Dysport Ò : Botox Ò ) have been suggested. [15] The amount of clostridial protein in Botox Ò and Dysport Ò is known -one vial of Botox Ò contains 5 ng of clostridial protein per 100 unit vial, [16] whereas one vial of Dysport Ò contains 4.35 ng of clostridial protein per 500 unit vial, [9] although earlier publications from the manufacturer stated there were 12.5 ng per vial (500 units). [17] Xeomin Ò is reported to contain approximately 0.6 ng of clostridial protein per 100 unit vial. [14] The amount of the 150 kD neurotoxin (i.e. the active substance) in Botox Ò and Dysport Ò is not published. There are two important reasons to know both the amount of clostridial protein and the amount of the 150 kD neurotoxin in these preparations. Firstly, accompanying proteins or impurities may stimulate the immune response against the therapeutic agent; [18] and secondly, the dose of the antigen (i.e. the injected amount of neurotoxin protein itself), as well as the injected amount of denatured/inactive neurotoxin, determines the immune response. Therefore, the aim of this study is to determine the concentration of the 150 kD neurotoxin in Botox Ò , Dysport Ò , and Xeomin Ò using a sensitive sandwich ELISA.
A similar study was carried out with Botox Ò and Dysport Ò but the results were reported anonymously. [19] Materials and Methods
Materials
The incubation buffer solutions that were used were phosphate buffered saline (PBS) + 0.1% bovine serum albumin (BSA) [ The 150 kD neurotoxin protein was purified from C. botulinum type A, strain ATCC 3502 ('Hall strain'), according to a modified protocol of DasGupta and Sathyamoorthy. [20] It was demonstrated by Western Blot that no complexing proteins were present using an antiserum provided by the NIBSC. Antibodies to the 150 kD neurotoxin were raised in rabbits and guinea pigs (Biogenes, Berlin, Germany) according to a standard protocol. The neurotoxin was detoxified by treatment with formaldehyde (0.4%, 15 days at 37°C).
Complexing proteins of botulinum toxin type A free from neurotoxin were prepared from the botulinum toxin complex produced according to the methods of Schantz and Johnson. [6] The botulinum toxin complex was dialysed against 50 mM TRIS (tris[hydroxymethyl] aminomethane)/ HCl pH = 7.9 and purified by column chromatography on Q sepharose (GE Healthcare, Freiburg, Germany) by elution of the bound complexing proteins with a NaCl gradient. Traces of BoNT/A were removed by affinity chromatography. The chromatography matrix was prepared by immobilizing rabbit antibodies against BoNT/A on a CNBr sepharose (GE Healthcare) according to the instructions of the supplier. During the affinity chromatography step, BoNT/A was bound to the affinity column whereas all complexing proteins were eluted in the flow through. The composition of the complexing proteins was not changed after chromatography.
ELISA Procedure
A sensitive sandwich ELISA, which employed rabbit and guinea pig antisera raised against the 150 kD neurotoxin, was used to measure the amount of BoNT , or 30 mL of the Dysport Ò (supplemented to a total volume of 100 mL with buffer solution 1) solution was pipetted into a Microtiter plate well coated with the anti-150 kD neurotoxin rabbit antisera and incubated for 1 hour at 37°C. Each vial was analyzed in triplicate.
Wells were washed five times with buffer solution 1, incubated with the anti-150 kD neurotoxin guinea pig antiserum diluted 1 : 2000 in buffer solution 2 for 1 hour at 37°C, then washed five times with buffer solution 1 to remove unbound antibodies. Bound 150 kD neurotoxin antibodies were detected by incubation for 1 hour at 37°C with an anti-guinea pig IgG peroxidase conjugate (Sigma, A 7289) diluted 1 : 5000 in buffer solution 2. After washing five times with buffer solution 1, the concentration of the bound conjugate was determined by incubation with o-phenylenediamine (16 mmol/L) in 10 mmol/L citrate buffer (pH = 5.0) containing 0.06% H 2 O 2 . The color reaction was stopped by the addition of 1 mol/L sulphuric acid.
The optical density of each well was measured at 490 nm on a Microtiter plate reader SpectraMax Plus (Molecular Devices, Sunnyvale, CA, USA) operated via the 'SoftMax Pro GxP' program. To quantify the concentration of the 150 kD neurotoxin, a standard curve was generated between 0.2 ng/mL and 1.6 ng/mL of the neurotoxin in steps of 0.2 ng/mL. Figure 1 depicts a representative standard curve covering a concentration range between 0.2 and 1.6 ng/mL. On each Microtiter plate, a control sample was analyzed to assess the validity of each assay. The ELISA was validated according to the International Conference on Harmonisation (ICH) [21] guidelines for linearity of the standard curve, specificity, precision, accuracy, and robustness. The specificity of the ELISA was determined by analyzing purified C. botulinum toxins type B (strain Okra), type C (provided by Wako Ltd, Osaka, Japan) and type E (strain ATCC 17854).
The 
Results

ELISA Specificity
Purified C. botulinum toxins type B, type C, and type E showed no signal at a maximum concentration of 100 ng/mL (data not shown), confirming the specificity of the ELISA assay for BoNT/A.
None of the product's excipients (sucrose and lactose) interfered with the ELISA assay (data not shown). Sodium chloride and human serum albumin were present in the same concentration in the samples. There was no reactivity when £10 ng/mL of complexing proteins, purified from the botulinum toxin complexes by affinity chromatography with immobilized neurotoxin, was tested in the ELISA (data not shown). A recovery of 97.3-100% was achieved by the ELISA when 0.9 ng/mL of the 150 kD neurotoxin protein was added to 10 ng/mL of complexing proteins. The ELISA detected denatured neurotoxin after heat treatment (5 days after 80°C). [22] Botulinum Neurotoxin Type A Concentration of Botox â , Dysport â , and Xeomin Ò found in the current study is lower than previously reported. [14] However, the higher sensitivity and precision of the ELISA assay used in the present investigation may have contributed to this discrepancy.
As mentioned in the introduction, the 150 kD neurotoxin is the only active pharmaceutical ingredient in Xeomin Ò . Like Xeomin Ò , the neurotoxin in Botox Ò and Dysport Ò (as part of the toxic complex) is derived from the Hall strain of C. botulinum type A and has an identical amino acid sequence. However, it cannot be excluded that there may be differences in the epitope structure of the neurotoxin in Botox Ò and Dysport Ò compared with Xeomin Ò because they are prepared according to different procedures, [6, 9] which may affect their relative reactivity to the antibody. Nevertheless, it may be speculated that the differing epitopes (by structure, if there were any) were not recognized by the applied antibodies that are highly specific for the neurotoxin in Xeomin Ò . If that were the case, the binding of the used antibodies to the neurotoxin in Botox Ò and Dysport Ò would be lower in the ELISA. Because the quantification of the ELISA depends on the binding of the antibodies to the substance to be analyzed, the relative concentration of the neurotoxin determined in the assay would be lower and the neurotoxin content in Botox Ò and Dysport Ò would be even higher than that described in this study. For a similar reason it would be problematical to apply an immunoassay based on monoclonal antibodies, because it has to be demonstrated that these antibodies react with respective epitopes of active as well as inactive BoNT/A in all products. Despite differences in specific neurotoxin activity (defined as the biologic activity in units per mass of neurotoxin protein), clinical studies have shown that the efficacy of Xeomin Ò and Botox Ò is comparable. [10] [11] [12] Dressler and colleagues [13] also showed an equivalent potency of Botox Ò and Xeomin Ò in a mouse LD 50 bioassay. Together, these results demonstrate that the amount of neurotoxin in Botox Ò and Xeomin Ò exhibits the same activity in the clinical environment as in the standard mouse in vivo assay. [14] From the results of the current study, one can propose that the 0.44 ng neurotoxin protein in 100 units of Xeomin Ò is as potent as the 0.73 ng neurotoxin protein in 100 units of Botox Ò . This suggests that Botox Ò contains a considerable amount of inactivated or partly denatured/ inactivated neurotoxin -a suggestion that is supported by a previous study that showed that the 900 kD complex had a specific activity of 3 -20% · 10 7 LD 50 units per mg of protein. [6] Thus, 100 units would correspond to 2.4-3.6 ng clostridial protein, which differs markedly from the 5 ng reported for Botox Ò in its prescribing information. [16] Of note, the presence of residual denatured/inactive neurotoxin in Botox Ò or Dysport Ò (i.e. a higher dose of antigen) can, amongst other factors, be associated with the stimulation of neurotoxin neutralizing antibodies in some patients.
The amount of neurotoxin in Botox Ò can also be estimated from the proportion of neurotoxin in the complex: the 150 kD neurotoxin should be one-sixth of the 900 kD complex (i.e. 5 ng/6 = 0.83 ng), which is similar to the 0.73 ng demonstrated in the present investigation. Our calculation is supported by a patent application filed by Allergan, which reported that the average specific potency of the purified complex before formulation was 28 pg protein/unit or 2.8 ng per 100 units. [23] Since Botox Ò contains 5 ng and not 2.8 ng clostridial protein, is it likely that part of the neurotoxin may be denatured, [24] possibly due to the use of sodium chloride in the formulation, which seems to be detrimental for activity during the drying process. [25] The current study found 3.24 ng per vial (500 units) of neurotoxin in Dysport Ò , corresponding to 0.65 ng per 100 units. Considering there is 4.35 ng of clostridial protein in a 500 unit vial of Dysport Ò , the proportion of the neurotoxin is approximately 70%, with around 30% made up of complexing proteins, and other clostridial proteins. [9] This calculation is consistent with a rough estimation of the proportion of the neurotoxin from the electrophoresis of three batches of Dysport Ò . [9] Although all complexing proteins were present in the drug substance, [9] the amount of these proteins in the preparation seems to be too low to form a high molecular weight complex with all neurotoxin molecules, hence, a part of the neurotoxin in Dysport Ò seems to be present as a free molecule.
In this study, a 100 unit vial of Xeomin Ò contained a mean concentration of BoNT/A neurotoxin of 0.44 ng. The high specific potency corresponds to high specific potency values in the literature for the purified BoNT/A. [26] The reason for the high specific activity in Xeomin Ò might be that no inactivation of the neurotoxin takes place during the manufacturing process of the drug product. As a result, the final Xeomin Ò product contains only the active neurotoxin. This is corroborated by the finding that the active substance before formulation and lyophilizing has the same specific potency as the final product. [27] Thus, although the amount of units of neurotoxin (specific biologic activity) is the same when Botox Ò or Xeomin Ò is administered to the patient, the amount of neurotoxin protein administered is different. Patients treated with Botox Ò receive about 60% more of neurotoxin protein, which represents denatured/inactive neurotoxin. This means that the dose of antigen is higher, which may be responsible for the formation of neutralizing antibodies leading to therapeutic failure. As a consequence, this could exclude, for instance, patients with dystonia or spasticity from receiving adequate treatment.
Conclusions
The current study has shown that of the three products investigated, Xeomin Ò contains the highest
